# Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab

> **NCT07520045** · NA · RECRUITING · sponsor: **Osijek University Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Diabetic Retinopathy (DR)
- Diabetic Macular Edema (DME)

## Interventions

- **DRUG:** Faricimab
- **DRUG:** Biosimilar ranibizumab

## Key facts

- **NCT ID:** NCT07520045
- **Lead sponsor:** Osijek University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-12
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07520045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07520045, "Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07520045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*